Study S001026

A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07099742
Study type: OBSERVATIONAL
Status: NOT_YET_RECRUITING
Enrollment: 364
Start: 2026-11
Primary completion: 2027-10
Lead sponsor: Dr. Md. Alimur Reza
Conditions: Obesity
Interventions: DRUG:Tirzepatide; BEHAVIORAL:Life Style Modification
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change in body weight at Week 24 in both treatment groups. [Baseline to 24 Weeks]
Percentage of participants withdrawn from the study due to adverse events by Week 24 [Up to Week 24]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0007405	Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Wadden TA, Nature medicine	2023	Randomized trial	PMID 37840095 DOI	registry reference BACKGROUND:37840095
R0010987	Tirzepatide Once Weekly for the Treatment of Obesity. Jastreboff AM, The New England journal of medicine	2022	Randomized trial	PMID 35658024 DOI	registry reference BACKGROUND:35658024
R0020960	Tirzepatide: A Systematic Update. Forzano I, International journal of molecular sciences	2022	Systematic review	PMID 36498958 DOI	registry reference BACKGROUND:36498958